Resurrect Bio celebrates $8.1M initial close of Series A
LONDON, Feb. 17, 2026 - Resurrect Bio, a biotechnology company and TSL spinout that's revolutionizing agriculture by equipping crops with genetic defenses against disease, announced the successful initial closing of its Series A funding round at $8.1M. The investment was led by Corteva through its Corteva Catalyst platform, with participation from Calculus Capital, Pymwymic, UKI2S, SynBioVen, and AgFunder.
"We're thrilled to have secured this investment from such a distinguished group of partners who share our vision of delivering durable disease resistance to farmers. With Corteva's leadership and the support of Calculus Capital, Pymwymic and our existing investors, we're now positioned to scale our platform and deliver multiple resistance traits to the seed industry."
Dr Cian Duggan
CEO of Resurrect Bio
"Resurrect Bio is a TSL spinout company founded on ground-breaking science, that will use precision breeding technology to combat some of the most important diseases facing global agriculture. We are very proud of the team led by Cian Duggan and excited to see their next stage of development.” - TSL Executive Director, Nick Talbot.
The completion of this Series A round represents a significant milestone for Resurrect Bio, reflecting growing industry recognition of the urgent need for sustainable crop protection solutions. The funds will enable Resurrect Bio to accelerate its high-throughput trait discovery platform and advance multiple disease resistance products toward commercial partnerships, bringing solutions to farmers significantly faster than conventional breeding methods.
“It’s incredibly rewarding to see years of fundamental research on plant immune receptors move one step closer to real-world impact. As a co-founder, I’m immensely proud of Cian and the team for driving Resurrect Bio to this milestone. We’re now poised to tackle some of agriculture’s toughest disease challenges with bold gene-editing solutions and help shape a more resilient, sustainable food system.”
Sophien Kamoun
Group Leader at The Sainsbury Laboratory & Resurrect Bio co-founder
Resurrect Bio's proprietary platform combines cutting-edge FloraFold® AI computational biology and high-throughput screening in plants to identify and resurrect disease resistance genes that have been suppressed by pathogens. The resurrection process involves making small changes to the native plant genes using gene editing, restoring the crop's ability to defend itself against pathogens. This approach is poised to offer farmers a novel pathway to protect yields against the plant diseases that threaten global food security.
"Our collaboration with Resurrect Bio signals another step in our journey to discover new technologies that provide farmers more sustainable crop protection solutions. We're excited to work with Resurrect Bio and explore the next generation of gene editing capabilities to further unlock the potential of our world-class germplasm." - Tom Greene, senior director at Corteva and global leader for Corteva Catalyst
Corteva, through its Corteva Catalyst platform, collaborates with entrepreneurs and innovators to accelerate the development of early-stage, disruptive technologies that enable farmers to sustainably produce more food and feed.
About Resurrect Bio
Resurrect Bio is a London-based agricultural biotechnology company developing disease-resistant crops through its proprietary gene editing platform. By resurrecting native resistance genes found in wild relatives and heritage varieties, Resurrect Bio provides the seed industry with a sustainable alternative to chemical crop protection. Spun out of The Sainsbury Laboratory in Norwich, Resurrect Bio was founded by Prof. Sophien Kamoun, Prof. Tolga Bozkurt, and Dr. Cian Duggan.
